Tag Archives: anticoagulant

New treatment for Atrial Fibrillation

Ever felt an odd flutter in your chest, as if your heart has suddenly squeezed in an extra beat? Most of us have at least one of these ‘ectopic’ beats a day, although we often don’t notice them. But if you have Atrial Fibrillation (AF), electrical impulses cause the upper chambers of your heart to beat in a chaotic way, and often so fast that the heart isn’t able to relax between contractions. It can mean that you’re left feeling tired, dizzy and short of breath. On the other hand you may not notice that anything’s wrong, until someone takes your pulse.

The more serious problem with AF, which affects around 10 percent of those over 75, is that it can increase the risk of a blood clot forming inside your heart. That clot can travel from the heart to the brain, leading to a stroke. AF can increase your risk of having a stroke by up to five times.

Whether you have a high, medium or low risk of having a stroke depends on a number of factors. These include your age, previous strokes or blood clots, high blood pressure and heart disease. If you have AF one of your doctor’s main concerns will be to reduce your risk of having a stroke.

Warfarin is the medication usually prescribed for most people with high to medium risk of stroke. It’s an anticoagulant, so it works by making your blood less likely to clot. Warfarin is effective, but it does have disadvantages. If you are on this drug, you have to go for repeat blood tests to check that your blood hasn’t become too thin. You also have to be very careful about what you eat and drink, as this can affect your blood. Some people who take warfarin find these restriction limit their ability to have a normal life.

Atrial fibrillation

Atrial fibrillation

NICE (the National Institute for Health and Clinical Excellence) has now approved a new drug, dabigatran (Pradaxa), as an option for the prevention of stroke and systemic embolism (a blockage in a blood vessel, caused, for instance, by a blood clot). However dabigatran hasn’t been recommended for everyone with AF. To be considered for this new treatment you have to fit a number of different criteria, including having nonvalvular AF, and being 65 or older, with one of the following conditions: diabetes mellitus, coronary artery disease or high blood pressure. NICE has recommended this new drug because “on balance, the benefits outweigh the risks, and it is seen as a cost-effective use of resources.”

What are the benefits? AF patients who take dabigatran don’t have to undergo the rigorous monitoring and repeat blood testing that comes with taking warfarin. And in trials, taking 150mg of dabigatran, twice daily, resulted in lower incidence of stroke and related conditions in clinical trials. So is it a clear-cut winner?


“Warfarin has been very important, and has been shown to substantially reduce your risk of stroke,” says Joe Korner, spokesperson for The Stroke Association. “But the problem is that it’s quite a difficult drug to administer, and people need to be monitored very regularly because if you have too much it can turn the problem of clotting into the problem of a bleed, and haemorrhage. That means that GPs are sometimes reluctant to prescribe it. That’s what we’ve had until now, and too often AF is left untreated.

“What’s important about Pradaxa is that it gives GPs another option, a different way of preventing blood clots. It’s not going to be a magic bullet, it isn’t going to replace warfarin, and there are some people for whom it may not be a better alternative. But the actual existence of an alternative treatment is really good. It means that people who can’t tolerate warfarin or who the GP is worried about may be able to get treatment.

“The other thing to bear in mind is that it’s a more expensive drug, (£2.52 a day per patient, compared to £1 a day for warfarin) so that’s an issue for the NHS. But the fact that NICE has approved it is an indication that the benefits of Pradaxa are worthwhile to the NHS.”

Saga Magazine’s Dr David Roche had this to say about the new drug, “dabigatran does the same job as warfarin, without some of its risks and the need for blood tests. It does, however, have some problems of its own. Unlike warfarin it cannot be reversed if you take too much.”

Aspirin may slash cancer risk by 60%

A DAILY dose of aspirin can slash the risk of developing bowel cancer by 60 per cent.

A ground-breaking trial has proved that taking two of the “wonder” pills a day gives long-term protection and could save thousands of lives each year.

Lead researcher Professor Sir John Burn, of the University of Newcastle, said: “We have finally shown that aspirin has a major preventative effect on cancer, but this doesn’t become apparent until years later.

“If you gave two aspirin a day for two years to people with hereditary bowel cancer, after five years their cancer risk will be reduced by more than half.”

The landmark British study was hailed by Professor Nick Hastie, director of the Medical Research Council Human Gen­etics Unit, as providing “the clearest evidence yet” that aspirin can protect against cancer.

He said: “As we learn more about the underlying mechanism of this effect, we will eventually be able to develop new ways of preventing and treating cancer.”

The study was carried out in patients at high risk of bowel cancer but experts hope the findings could have wider implications in the general population.

There was also evidence of a similar impact on cancers with the same genetic link – womb, ovarian, pancreatic, brain, stomach and kidney.

Further research is to be carried out, but the researchers said people with a family history of bowel cancer may want to start taking a low dose of aspirin as a preventative measure after first discussing it with their doctor.

Aspirin

Aspirin

The study, called CAPP2 and published online in The Lancet, provides the most definitive evidence yet of aspirin’s anti-cancer properties.

It focused on patients with Lynch syndrome, a genetic fault that strongly predisposes people to bowel cancer.

Around one in 1,000 of the population carry the genes, which account for one in 30 cases of bowel cancer.

Those affected are 10 times more likely than average to develop cancer.

Each year around 40,000 people in Britain are diagnosed with bowel cancer and more than 16,000 die from it.

The findings suggest aspirin treatment could prevent up to 10,000 cancers over the next 30 years and possibly save 1,000 lives. Despite taking large doses of aspirin – two 300 milligram pills per day – patients suffered no adverse effects.

Aspirin is known to raise the risk of strokes, internal bleeding and stomach ulcers, so there is a trade-off.


It is given to people at risk of heart attacks or stroke. As a long-term anticoagulant or a preventative measure for heart disease, the dose is 75mg a day. As a painkiller, the recommended dose is 275 to 300mg, not exceeding three doses a day.

A new investigation will look at the dose needed to prevent cancer.

The CAPP2 study between 1999 and 2005 involved 861 people identified as Lynch syndrome carriers and given aspirin or a placebo.

Results in 2007 showed no difference in bowel cancer rates. But by 2010 there was a 44 per cent reduced incidence rate linked to the aspirins.

Further analysis of the 60 per cent who took aspirin for at least two years revealed a 63 per cent difference.

Professor Chris Paraskeva, Cancer Research UK’s bowel cancer expert, said: “This adds to the growing body of evidence showing the importance of aspirin in the fight against cancer.”

Mark Flannagan, chief executive of Beating Bowel Cancer, said: “These results are really very promising.”